Baseline characteristics of patients enrolled in study
| Patient study number . | Age at mobilization, y . | MPD diagnosis (years' duration) . | Prior treatment . | Blood counts at study entry . | Spleen size* . | Baseline cytogenetics . | Indication for transplantation . | Peripheral blood CD34+ (cells/μL) . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| WBC (× 109/L) . | HCT (%) . | PLT (× 109/L) . | ||||||||
| 01-001 | 67 | AMM (1.5) | RBC TX | 28.2 | 29.2 | 272 | 18 | Normal | Anemia, splenomegaly, leukemic progression (12% blasts) | 3,575 |
| 01-002 | 69 | AMM (4) | IFN, EPO, RBC TX | 7 | 26 | 143 | 17 | del(12q)der(15), t(1;15) | Anemia, splenomegaly | 62 |
| 01-003 | 75 | AMM (0.75) | RBC TX | 13.3 | 31‡ | 166 | 20 | Normal | Anemia, splenomegaly | 128 |
| 01-004 | 45 | AMM (0.5) | HU, RBC TX | 3.6 | 22.6 | 193 | Tip palpable | Normal | Anemia | 119 |
| 01-005 | 68 | AMM (0.4) | EPO, HU, RBC TX | 17.5 | 27.1 | 224 | 8 | del(12p) | Anemia, leukocytosis | ND |
| 01-006 | 65 | AMM (6.3) | RBC TX | 10.2 | 27.8 | 338 | 12 | inv(12p) | Anemia, splenomegaly | 131.6 |
| 02-001 | 54 | AMM (2.25) | EPO, RBC TX | 4.1 | 31.22-153 | 167 | 21 | Normal | Anemia, splenomegaly | 80 |
| 02-002 | 61 | AMM (17) | Steroids, Splen, RBC TX | 23.3 | 21.5 | 109 | Absent | (7;?7), del(13q) | Anemia | 299 |
| 02-003 | 54 | PPMF (1.7) PV (14) | Splen, HU | 6.5 | 38 | 390 | Absent | Normal | Too early for transplantation | 3.2 |
| 02-004 | 69 | AMM (3.5) | Steroids, RBC TX | 7.4 | 29.4 | 60 | Into pelvis | Normal | Anemia, splenomegaly | 108.6 |
| 02-005 | 54 | AMM (0.8) | RBC TX | 5.8 | 26.4 | 121 | Not palpable† | Normal | Anemia | 11.7 |
| 02-006 | 64 | AMM (1.7) | EPO, RBC TX | 4.0 | 28.0 | 79 | 2 | −7, del(20q) | Anemia | 9.7 |
| 02-007 | 59 | AMM (0.3) | Steroids, RBC TX | 3.2 | 26 | 192 | Not palpable† | Normal | Anemia | ND |
| 02-008 | 58 | AMM (3) ET (10) | RBC + platelet TX, steroids, HU | 1.6 | 22.8 | 29 | 7 | +16, +8, del(1) | Pancytopenia, bone pain, leukemic progression (17% blasts) | 284 |
| 02-009 | 52 | AMM (1) | None | 4.5 | 28.7 | 276 | 2 | Normal | Anemia | 27.4 |
| 02-010 | 62 | PPMF (0.7) PV (5) | CHL, DXR phlebotomy, HU | 5.6 | 32.5 | 15 | Into pelvis | Normal | Leukocytosis, thrombocytopenia | ND |
| 02-011 | 51 | AMM (0.8) | None | 5.6 | 32.4 | 188 | 8 | Normal | Too early for transplantation | 42.5 |
| 02-012 | 49 | AMM (1) ET (20) | None | 27.6 | 32.1 | 55 | 17 | del(13q) | Organomegaly, portal hypertension, leukemic progression (12% blasts) | ND |
| 02-013 | 57 | AMM (> 10) | Splen | 15.3 | 35.7 | 31 | Absent | ND | Thrombocytopenia, bone pain | ND |
| 02-014 | 52 | AMM (9) | HU, Steroids, RBC TX | 5.4 | 24.2 | 290 | 232-155 | add (9p), add (21q) | Anemia | ND |
| 02-015 | 54 | AMM (24) | Platelet + RBC TX, HU, Splen, IFN, G-CSF, steroids | 28.8 | 30.7 | 15 | Absent | normal | Anemia, thrombocytopenia, leukemic progression (20% blasts) | ND |
| 03-001 | 52 | AMM (0.2) ET (18) | Platelet + RBC TX | 3.6 | 21.6 | 10 | 14 | Complex, including del(5q), del(7q) | Leukemic progression (13% blasts), pancytopenia, splenomegaly | ND |
| 03-002 | 62 | PPMF (3) PV (14) | Phelbotomy, steroids, HU, EPO, CSP, IFN, AZO, Splen, RBC TX, Pamid | 11.3 | 35.9 | 56 | Absent | Normal | Anemia, bone pain | ND |
| 03-003 | 49 | AMM (3.3) | IFN, HU, steroids, Pamid, Thal | 5.0 | 27.5 | 252 | 11 | del(13q) | Bone pain, splenomegaly, leukocytosis, thrombocytosis | ND |
| 03-004 | 65 | AMM (0.3) | HU, EPO | 5.5 | 24.2 | 72 | 26 | −7, del(7q) | Organomegaly, anemia | 73.2 |
| 03-005 | 64 | AMM (0.3) ET (11) | Steroids, RBC TX, HU | 0.8 | 19.6 | 119 | 13.5 | Normal | Leukemic progression (15% blasts), pancytopenia, organomegaly | ND |
| 04-001 | 48 | AMM (2) ET (10) | RBC TX | 2.6 | 22 | 36 | 23 | ND | Anemia, splenomegaly | ND |
| Patient study number . | Age at mobilization, y . | MPD diagnosis (years' duration) . | Prior treatment . | Blood counts at study entry . | Spleen size* . | Baseline cytogenetics . | Indication for transplantation . | Peripheral blood CD34+ (cells/μL) . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| WBC (× 109/L) . | HCT (%) . | PLT (× 109/L) . | ||||||||
| 01-001 | 67 | AMM (1.5) | RBC TX | 28.2 | 29.2 | 272 | 18 | Normal | Anemia, splenomegaly, leukemic progression (12% blasts) | 3,575 |
| 01-002 | 69 | AMM (4) | IFN, EPO, RBC TX | 7 | 26 | 143 | 17 | del(12q)der(15), t(1;15) | Anemia, splenomegaly | 62 |
| 01-003 | 75 | AMM (0.75) | RBC TX | 13.3 | 31‡ | 166 | 20 | Normal | Anemia, splenomegaly | 128 |
| 01-004 | 45 | AMM (0.5) | HU, RBC TX | 3.6 | 22.6 | 193 | Tip palpable | Normal | Anemia | 119 |
| 01-005 | 68 | AMM (0.4) | EPO, HU, RBC TX | 17.5 | 27.1 | 224 | 8 | del(12p) | Anemia, leukocytosis | ND |
| 01-006 | 65 | AMM (6.3) | RBC TX | 10.2 | 27.8 | 338 | 12 | inv(12p) | Anemia, splenomegaly | 131.6 |
| 02-001 | 54 | AMM (2.25) | EPO, RBC TX | 4.1 | 31.22-153 | 167 | 21 | Normal | Anemia, splenomegaly | 80 |
| 02-002 | 61 | AMM (17) | Steroids, Splen, RBC TX | 23.3 | 21.5 | 109 | Absent | (7;?7), del(13q) | Anemia | 299 |
| 02-003 | 54 | PPMF (1.7) PV (14) | Splen, HU | 6.5 | 38 | 390 | Absent | Normal | Too early for transplantation | 3.2 |
| 02-004 | 69 | AMM (3.5) | Steroids, RBC TX | 7.4 | 29.4 | 60 | Into pelvis | Normal | Anemia, splenomegaly | 108.6 |
| 02-005 | 54 | AMM (0.8) | RBC TX | 5.8 | 26.4 | 121 | Not palpable† | Normal | Anemia | 11.7 |
| 02-006 | 64 | AMM (1.7) | EPO, RBC TX | 4.0 | 28.0 | 79 | 2 | −7, del(20q) | Anemia | 9.7 |
| 02-007 | 59 | AMM (0.3) | Steroids, RBC TX | 3.2 | 26 | 192 | Not palpable† | Normal | Anemia | ND |
| 02-008 | 58 | AMM (3) ET (10) | RBC + platelet TX, steroids, HU | 1.6 | 22.8 | 29 | 7 | +16, +8, del(1) | Pancytopenia, bone pain, leukemic progression (17% blasts) | 284 |
| 02-009 | 52 | AMM (1) | None | 4.5 | 28.7 | 276 | 2 | Normal | Anemia | 27.4 |
| 02-010 | 62 | PPMF (0.7) PV (5) | CHL, DXR phlebotomy, HU | 5.6 | 32.5 | 15 | Into pelvis | Normal | Leukocytosis, thrombocytopenia | ND |
| 02-011 | 51 | AMM (0.8) | None | 5.6 | 32.4 | 188 | 8 | Normal | Too early for transplantation | 42.5 |
| 02-012 | 49 | AMM (1) ET (20) | None | 27.6 | 32.1 | 55 | 17 | del(13q) | Organomegaly, portal hypertension, leukemic progression (12% blasts) | ND |
| 02-013 | 57 | AMM (> 10) | Splen | 15.3 | 35.7 | 31 | Absent | ND | Thrombocytopenia, bone pain | ND |
| 02-014 | 52 | AMM (9) | HU, Steroids, RBC TX | 5.4 | 24.2 | 290 | 232-155 | add (9p), add (21q) | Anemia | ND |
| 02-015 | 54 | AMM (24) | Platelet + RBC TX, HU, Splen, IFN, G-CSF, steroids | 28.8 | 30.7 | 15 | Absent | normal | Anemia, thrombocytopenia, leukemic progression (20% blasts) | ND |
| 03-001 | 52 | AMM (0.2) ET (18) | Platelet + RBC TX | 3.6 | 21.6 | 10 | 14 | Complex, including del(5q), del(7q) | Leukemic progression (13% blasts), pancytopenia, splenomegaly | ND |
| 03-002 | 62 | PPMF (3) PV (14) | Phelbotomy, steroids, HU, EPO, CSP, IFN, AZO, Splen, RBC TX, Pamid | 11.3 | 35.9 | 56 | Absent | Normal | Anemia, bone pain | ND |
| 03-003 | 49 | AMM (3.3) | IFN, HU, steroids, Pamid, Thal | 5.0 | 27.5 | 252 | 11 | del(13q) | Bone pain, splenomegaly, leukocytosis, thrombocytosis | ND |
| 03-004 | 65 | AMM (0.3) | HU, EPO | 5.5 | 24.2 | 72 | 26 | −7, del(7q) | Organomegaly, anemia | 73.2 |
| 03-005 | 64 | AMM (0.3) ET (11) | Steroids, RBC TX, HU | 0.8 | 19.6 | 119 | 13.5 | Normal | Leukemic progression (15% blasts), pancytopenia, organomegaly | ND |
| 04-001 | 48 | AMM (2) ET (10) | RBC TX | 2.6 | 22 | 36 | 23 | ND | Anemia, splenomegaly | ND |
MPD indicates myeloproliferative disorder; WBC, white blood cell count; HCT, hematocrit; PLT, platelet count; AMM, agnogenic myeloid metaplasia; RBC TX, red cell transfusion; IFN, interferon; EPO, erythropoietin; HU, hydroxyurea; Splen, splenectomy; ND, not done; PPMF, postpolycythemia myelofibrosis; PV, polycythemia vera; G-CSF, granulocyte colony-stimulating factor; ET, essential thrombocytosis; CHL, chlorambucil; DXR, doxorubicin; CSP, cyclosporine; AZO, azothioprine; Pamid, pamidronate; Thal, thalidomide.
Number of centimeters below the left costal margin.
Imaging studies showed enlarged spleen.
RBC TX-dependent, pretransfusion HCT was < 27.
Pre-EPO treatment HCT was 25.7.
Spleen size measured as craniocaudal length by ultrasound.